Tag: ALK

What is Anaplastic Large Cell Lymphoma?

Anaplastic large cell lymphoma (ALCL) is a rare subtype of non-Hodgkin’s lymphoma (NHL), a group of blood cancers that affect while blood cells called lymphocytes. With NHL, the lymphocytes grow out of control. These cells are a part of the immune system which helps protect your body from germs and…

Continue Reading What is Anaplastic Large Cell Lymphoma?

Can sf3b1 mutation be detected by rflp method?

Can sf3b1 mutation be detected by ARMS-PCR method?5 answersSF3B1 mutations can be detected using the ARMS-ddPCR method, which combines the amplification refractory mutation system (ARMS) with droplet digital polymerase chain reaction (ddPCR). This method allows for the detection of gene mutations at specific sites, including SF3B1 mutations, with high sensitivity…

Continue Reading Can sf3b1 mutation be detected by rflp method?

Expert Guidelines Detail Optimal Sequencing of Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer, Journal Club

Read the Full Video Transcript Rashid Sayyid: Hello everyone and thank you for joining us in this UroToday recording. I’m Rashid Sayyid, the Urologic Oncology Fellow at the University of Toronto, and along with Zach Klaassen, Associate Professor Program Director at Wellstar MCG Health, we’ll be discussing the recently amended…

Continue Reading Expert Guidelines Detail Optimal Sequencing of Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer, Journal Club

Whole-genome sequencing reveals the molecular implications of the stepwise progression of lung adenocarcinoma

Whole-genome sequencing (WGS) analysis of early and advanced adenocarcinomas Whole-genome short read and long read sequencing datasets of 76 lung cancer specimens were analyzed. The datasets included newly generated data for 48 early small-sized lung adenocarcinoma cases (collectively called “Early-Ad” hereafter). These cases included 26 AIS (9 and 17 cases…

Continue Reading Whole-genome sequencing reveals the molecular implications of the stepwise progression of lung adenocarcinoma

Formononetin | FGFR2 inhibitor | Axon 4067

All All Products Enzymes Receptors Ion Channels Research Areas Oxidoreductases Transferases Lyases Isomerases Ligases Nuclear Receptors Ligand-gated ATP-Sensitive Angiogenesis Apoptosis Cardiovascular Cell Cycle Regulation Cell Signaling & Oncology CNS Diabetes & Metabolism Epigenetics Immunology Miscellaneous Pain & Inflammation Stem Cell Oxidases MAO Cys-loop, cationic Cis-Trans Isomerase CypA DNA Topoisomerase Synthetases…

Continue Reading Formononetin | FGFR2 inhibitor | Axon 4067

Valemetostat Provides “Clinically Meaningful Benefit” in Relapsed/Refractory PTCL

Valemetostat has demonstrated activity in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), according to research presented at the ASH Annual Meeting 2023. “Valemetostat demonstrated high rates of response and durable responses in patients with relapsed/refractory peripheral T-cell lymphoma,” said study presenter Steven M. Horwitz, MD, of Memorial Sloan…

Continue Reading Valemetostat Provides “Clinically Meaningful Benefit” in Relapsed/Refractory PTCL

Human Gene Mutation Test Kit Market to witness tremendous growth by 2029 |NuProbe, Integrated DNA Technologies, New England Biolabs, GenScript, CD Genomics

[New York, November 2023] — An insightful market analysis report focusing on the Human Gene Mutation Test Kit Market has just been released by Stats N Data, serving as a valuable resource for both industry leaders and newcomers. This comprehensive report offers a detailed exploration of the global Human Gene…

Continue Reading Human Gene Mutation Test Kit Market to witness tremendous growth by 2029 |NuProbe, Integrated DNA Technologies, New England Biolabs, GenScript, CD Genomics

2023-12-08 | NYSE:MRK | Press Release

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, did not meet its dual primary endpoints of overall…

Continue Reading 2023-12-08 | NYSE:MRK | Press Release

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma -December 08, 2023 at 06:47 am EST

Merck and Eisai announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of patients with…

Continue Reading Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma -December 08, 2023 at 06:47 am EST

Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

PRINCETON, N.J.–(BUSINESS WIRE)–   Bristol Myers Squibb Company Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary Endpoint Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -8HW trial evaluating…

Continue Reading Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

Anaplastic Large Cell Lymphoma Therapeutics Market Research Report Provides thorough Industry Overview, which offers an In-Depth Analysis of Product T

Market Overview and Report Coverage Anaplastic Large Cell Lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma that primarily affects the lymph nodes and skin. It is characterized by the abnormal growth of large cells called anaplastic lymphoma kinase (ALK)-positive or ALK-negative lymphoma cells. The ALCL therapeutics market pertains to…

Continue Reading Anaplastic Large Cell Lymphoma Therapeutics Market Research Report Provides thorough Industry Overview, which offers an In-Depth Analysis of Product T

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma, Business News

ROCKVILLE, Md. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the interim analysis results of ORIENT-16, the Phase 3 study evaluating…

Continue Reading Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma, Business News

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma USA – English APAC – Traditional Chinese APAC – English

ROCKVILLE, Md. and SUZHOU, China, Dec. 5, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the interim analysis results of ORIENT-16, the Phase 3 study evaluating…

Continue Reading Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma USA – English APAC – Traditional Chinese APAC – English

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic…

Application based on results from the Phase 3 CheckMate -901 trial showing significant survival improvement vs. standard-of-care gemcitabine plus cisplatin in cisplatin-eligible patients with untreated, unresectable or metastatic urothelial carcinoma If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the U.S. The…

Continue Reading U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic…

NOTCH1 mutations predict superior outcomes, NSCLC

Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide, and the majority are non-small-cell lung cancer (NSCLC).1,2 Genetic variation is a typical feature of NSCLC that drives cancer initiation and progression.3 Understanding the role of mutated genes in NSCLC is the basis of the development of novel treatment…

Continue Reading NOTCH1 mutations predict superior outcomes, NSCLC

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL

Popis Simple Summary In general, the non-Hodgkin lymphoma (NHL), anaplastic large cell lymphoma (ALCL) diagnosed in childhood has a good survival outcome when treated with multi-agent chemotherapy. However, side effects of treatment are common, and outcomes are poorer after relapse, which occurs in up to 30% of…

Continue Reading Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy | Molecular Cancer

Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019;20:377–88. Article  CAS  PubMed  PubMed Central  Google Scholar  Li L, Papadopoulos V. Advances in stem cell research for the treatment of primary hypogonadism. Nat Rev Urol. 2021;18:487–507. Article  CAS  PubMed  Google Scholar  Lawrence…

Continue Reading Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy | Molecular Cancer

Mutation of key signaling regulators of cerebrovascular development in vein of Galen malformations

Adams, R. H. & Eichmann, A. Axon guidance molecules in vascular patterning. Cold Spring Harb. Perspect. Biol. 2, a001875 (2010). Article  PubMed  PubMed Central  Google Scholar  Fish, J. E. & Wythe, J. D. The molecular regulation of arteriovenous specification and maintenance. Dev. Dyn. 244, 391–409 (2015). Article  CAS  PubMed  Google…

Continue Reading Mutation of key signaling regulators of cerebrovascular development in vein of Galen malformations

Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431

Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC Background Combination chemotherapy + pembrolizumab is 1L SOC for patients without an EGFR or ALK alteration RET gene fusions are targetable alterations for some patients with NSCLC Selpercatinib is a highly selective RET kinase inhibitor…

Continue Reading Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431

ALK+ ALCL with erythroblast-like cytology diagnosed in ascites in a patient with history of B-cell lymphomas | Blood

A 42-year-old woman with a history of marginal zone lymphoma (8 years ago) with diffuse large B-cell lymphoma transformation (4 years ago) was admitted with shortness of breath, bilateral pleural effusions, and ascites. A paracentesis of ascites was performed, and cytology smears showed many large-sized atypical cells with abundant basophilic…

Continue Reading ALK+ ALCL with erythroblast-like cytology diagnosed in ascites in a patient with history of B-cell lymphomas | Blood

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla, Inc. Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be presented at upcoming IASLC conference in early December and discussed at KOL event on December 4, 2023 Observed new PRs with…

Continue Reading BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Chromosome-level genomes of three key Allium crops and their trait evolution

Chase, M. W. et al. An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants: APG IV. Bot. J. Linn. Soc. 181, 1–20 (2016). Article  Google Scholar  Jones, M. G. et al. Biosynthesis of the flavour precursors of onion and garlic. J. Exp. Bot….

Continue Reading Chromosome-level genomes of three key Allium crops and their trait evolution

Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib

. 2023 Sep;202(5):985-994. doi: 10.1111/bjh.18953. Epub 2023 Jun 25. Nina Prokoph  1 , Jamie D Matthews  1 , Ricky M Trigg  1 , Ivonne A Montes-Mojarro  2 , G A Amos Burke  3 , Falko Fend  2 , Olaf Merkel  4 , Lukas Kenner  4   5   6   7 , Birgit Geoerger  8   9 , Robert…

Continue Reading Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib

Mutations That Matter in Lung Cancer and the Treatments Available for Them

When you hear the term “lung cancer” there are probably a lot of ideas and emotions that come to mind. Lung cancer is one of the most common cancers diagnosed and is the leading cause of cancer-death worldwide. Despite this, treatments and life expectancy have continued to improve over the…

Continue Reading Mutations That Matter in Lung Cancer and the Treatments Available for Them

Breast implant-associated anaplastic large cell lymphoma

INTRODUCTION — Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon and still emerging peripheral T cell lymphoma caused by and arising around textured-surface breast implants placed for either reconstructive or cosmetic indications. The association of breast implants with a cancer of the immune system has created understandable concern among patients,…

Continue Reading Breast implant-associated anaplastic large cell lymphoma

ASCO Reading Room | Personalized Upfront Treatments for Rare Lymphomas

As with many cancers, personalized therapy has replaced a one-size-fits-all approach for the frontline management of some nodal peripheral T-cell lymphomas (PTCLs). Although these represent only about 10-15% of all non-Hodgkin lymphomas, they encompass a diverse group with more than 30 different subtypes that share a common derivation from either…

Continue Reading ASCO Reading Room | Personalized Upfront Treatments for Rare Lymphomas

ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC

Alectinib, a potent anaplastic lymphoma kinase (ALK) inhibitor, significantly improved disease-free survival (DFS) at 2 years compared with chemotherapy in patients with completely resected ALK+ non–small cell lung cancer (NSCLC), according to interim findings from the open-label phase 3 ALINA trial. The results suggest that alectinib, which is currently the…

Continue Reading ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC

Alectinib shows promise in phase 3 ALINA trial for non-small cell lung cancer By Investing.com

© Reuters. The 2023 ESMO Congress showcased the results of the phase 3 ALINA trial, revealing that alectinib, an oral ALK inhibitor, significantly improved disease-free survival (DFS) in patients with resected stage IB-IIIA non–small cell lung cancer (NSCLC). The study was led by Ben Solomon at Australia’s Peter MacCallum Cancer…

Continue Reading Alectinib shows promise in phase 3 ALINA trial for non-small cell lung cancer By Investing.com

Perioperative Nivolumab Significantly Improves EFS in Previously Untreated Resectable NSCLC

Neoadjuvant treatment with nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab resulted in a statistically significant improvement in event-free survival (EFS) vs placebo plus chemotherapy, in patients with previously untreated resectable stage II to IIIB non-small cell lung cancer (NSCLC), according to data from the phase 3 CheckMate…

Continue Reading Perioperative Nivolumab Significantly Improves EFS in Previously Untreated Resectable NSCLC

Addition of Adjuvant Nivolumab Improves EFS in NSCLC

Surgery and adjuvant nivolumab (Opdivo) given after a treatment regimen of neoadjuvant nivolumab plus chemotherapy, showed a significant event-free survival (EFS) benefit for patients with previously untreated resectable stage II to IIIB non-small cell lung cancer (NSCLC), according to data presented at the 2023 ESMO Congress.1 These data came from…

Continue Reading Addition of Adjuvant Nivolumab Improves EFS in NSCLC

Neoadjuvant, Adjuvant Nivolumab Improves EFS in Resectable NSCLC

Neoadjuvant treatment with nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab significantly improved event-free survival (EFS), compared with placebo plus chemotherapy, in patients with previously untreated resectable stage II to IIIB non-small cell lung cancer (NSCLC), according to data from the phase 3 CheckMate 77T trial (NCT04025879) presented…

Continue Reading Neoadjuvant, Adjuvant Nivolumab Improves EFS in Resectable NSCLC

Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Antibodies

Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma Details Category: Antibodies Published on Thursday, 19 October 2023 13:34 Hits: 279 Subcutaneous nivolumab demonstrates noninferior pharmacokinetics (co-primary endpoints) and objective response rate (key secondary endpoint) compared…

Continue Reading Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Antibodies

Phase 3 ALINA Study of Alectinib Shows DFS Benefit in ALK+ NSCLC

Illustration of Lungs, medical concept© yodiyim – stock.adobe.com A statistically significant and clinically meaningful improvement in disease-free survival (DFS) was observed with alectinib (Alecensa) in patients with completely resected stage IB to IIIA ALK-positive non–small cell lung cancer (NSCLC), according to results from the primary analysis of the phase 3…

Continue Reading Phase 3 ALINA Study of Alectinib Shows DFS Benefit in ALK+ NSCLC

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

Roche has shared new results from a late-stage study of its anaplastic lymphoma kinase (ALK) inhibitor Alecensa (alectinib) in early-stage lung cancer. The phase 3 ALINA study has been evaluating the targeted drug as an adjuvant therapy in patients with completely resected stage 1B to 3A ALK-positive non-small cell lung…

Continue Reading Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

SHANGHAI, Oct. 10, 2023 /PRNewswire/ — GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first subject was dosed in a phase Ib/II trial of GFH009 (a highly selective CDK9 inhibitor) treating relapsed/refractory PTCL (peripheral T-cell lymphomas) patients. Designed to enroll…

Continue Reading GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL – No Study Results Posted

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.   ClinicalTrials.gov Identifier: NCT02462538 Recruitment Status : Terminated (Due to slow recruitment, recruitment…

Continue Reading Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL – No Study Results Posted

How is ALCL Staged and Classified?

Anaplastic Large Cell Lymphoma (ALCL) is classified and staged using several different systems depending on the subtype of ALCL a person has. The Ann Arbor Staging System This is the most commonly used system for staging lymphomas. It is used to evaluate the extent of disease in patients with systemic anaplastic…

Continue Reading How is ALCL Staged and Classified?

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients with Certain Types of Metastatic Non-Small Cell Lung Cancer -September 25, 2023 at 10:05 am EDT

RAHWAY – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck‘s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain…

Continue Reading Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients with Certain Types of Metastatic Non-Small Cell Lung Cancer -September 25, 2023 at 10:05 am EDT

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol-Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). In a prespecified interim analysis,…

Continue Reading Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo

Phase 3 trials of pembrolizumab plus lenvatinib in metastatic NSCLC miss primary endpoints

September 22, 2023 1 min read ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Continue Reading Phase 3 trials of pembrolizumab plus lenvatinib in metastatic NSCLC miss primary endpoints

List of Anaplastic Large Cell Lymphoma – ALK-Positive Medications

Other names: ALCL ALK; ALCL ALK-Positive; ALK-Positive ALCL Anaplastic large cell lymphoma (ALCL) is a rare form of non-Hodgkin lymphoma (NHL). Patients with ALK-positive ALCL have a mutation in their anaplastic lymphoma kinase (ALK) gene. ALCL – ALK-positive, is a fast-growing (aggressive) cancer, most common in children and young adults. Symptoms of ALCL…

Continue Reading List of Anaplastic Large Cell Lymphoma – ALK-Positive Medications

AEGEAN Study: Durvalumab Surgical Outcomes at IASLC 2023

[Singapore, 10:05 a.m. SGT–September 11, 2023] – Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented today from the phase 3 AEGEAN trial at the International Association for the Study…

Continue Reading AEGEAN Study: Durvalumab Surgical Outcomes at IASLC 2023

Lucence Presses Forward With Favorable Results From Liquid Biopsy Lung Cancer Studies

This article has been updated to provide greater clarity on the comparisons made in the Liquik study. NEW YORK – Precision oncology company Lucence plans to present interim results from the ongoing Liquik liquid biopsy lung cancer study and data pointing toward the potential benefits of cell-free RNA testing for earlier…

Continue Reading Lucence Presses Forward With Favorable Results From Liquid Biopsy Lung Cancer Studies

DelveInsight Highlights Major Advances, Transformative Therapies, and 7+ Leading Players Wheeling the Anaplastic Large Cell Lymphoma Clinical Trial Pipeline Landscape

PRESS RELEASE Published September 7, 2023 The Anaplastic Large Cell Lymphoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Anaplastic Large Cell Lymphoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to…

Continue Reading DelveInsight Highlights Major Advances, Transformative Therapies, and 7+ Leading Players Wheeling the Anaplastic Large Cell Lymphoma Clinical Trial Pipeline Landscape

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC

3D illustration of lung tumor © SciePro – stock.adobe.com Progression-free survival (PFS) results with brigatinib (Alunbrig) were not superior to that observed with alectinib (Alecensa) in crizotinib (Xalkori)-pretreated patients with ALK-positive non–small cell lung cancer (NSCLC), according to findings from the phase 3 ALTA-3 study (NCT03596866).1 Though brigatinib was not…

Continue Reading Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC

Phase 3 Trial Results Show Adjuvant Alectinib Reduces Recurrence, Mortality in Early-Stage ALK-Positive NSCLC

The phase 3 ALINA study (NCT03456076) evaluating adjuvant alectinib (Alecensa; Roche) against an adjuvant platinum-based chemotherapy met its projected goal of disease-free survival (DFS) at a prespecified interim analysispoint, according to study investigators. Compared to adjuvant platinum-based chemotherapy, alectinib showed a statistically significant and clinically meaningful improvement in DFS in…

Continue Reading Phase 3 Trial Results Show Adjuvant Alectinib Reduces Recurrence, Mortality in Early-Stage ALK-Positive NSCLC

Roche’s Alecensa smashes phase 3 as adjuvant therapy for lung cancer

Lung cancer is one of the leading causes​ of cancer deaths globally, with NSCLC being one of the most common forms of the disease. Additionally, many early lung cancer cases recur after surgery, despite modern treatment approaches including adjuvant chemotherapy and immunotherapy. Alecensa is a small molecule drug designed to…

Continue Reading Roche’s Alecensa smashes phase 3 as adjuvant therapy for lung cancer

Groundbreaking Findings from Phase 3 ALINA Study Show Alecensas Potential as Adjuvant Therapy for ALKPositive NSCLC

On September 1, 2023, Roche’s Alecensa (alectinib) revealed groundbreaking findings from the Phase 3 ALINA study. This study demonstrated a remarkable advancement in disease-free survival (DFS) for individuals with completely resected stage IB anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who received Alecensa as adjuvant therapy. The improvement…

Continue Reading Groundbreaking Findings from Phase 3 ALINA Study Show Alecensas Potential as Adjuvant Therapy for ALKPositive NSCLC

Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-010 Trial of KEYTRUDA pus LENVIMA

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, as a first-line treatment for patients…

Continue Reading Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-010 Trial of KEYTRUDA pus LENVIMA

Are cis-spliced fusion proteins pathological?

Three-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Image created in 2014 by Tom Misteli, Ph.D., and Karen Meaburn, Ph.D. at the NIH IRP. A new editorial paper titled “Are cis-spliced fusion proteins pathological in more aggressive…

Continue Reading Are cis-spliced fusion proteins pathological?

Are Cis-Spliced Fusion Proteins Pathological in Aggressive Luminal Breast Cancer?

“Our findings may provide a useful therapeutic approach for treating breast cancer patients who may suffer from early relapse and intrinsic resistance.” BUFFALO, NY- August 16, 2023 – A new editorial paper was published in Oncotarget’s Volume 14 on June 12, 2023, entitled, “Are cis-spliced fusion proteins pathological in more…

Continue Reading Are Cis-Spliced Fusion Proteins Pathological in Aggressive Luminal Breast Cancer?

Epithelioid inflammatory myofibroblastic sarcoma: a pitfall in the differential diagnosis of ALK-positive anaplastic large cell lymphoma

An 18-year-old female presented with a 4.5 cm abdominal mass. Biopsy showed sheet-like growth of large tumor cells with round to oval nuclei, 1-2 nucleoli, and abundant cytoplasm. Immunohistochemistry showed strong, uniform CD30 staining and cytoplasmic ALK staining. B-cell markers (CD20, CD79a, PAX5, kappa/lambda) and T-cell markers (CD2, CD3, CD4,…

Continue Reading Epithelioid inflammatory myofibroblastic sarcoma: a pitfall in the differential diagnosis of ALK-positive anaplastic large cell lymphoma

Phase 3 Study of Selpercatinib Meets Primary PFS End Point in NSCLC

Topline results from the LIBRETTO-431 trial of selpercatinib in RET fusion-positive advanced or metastatic NSCLC build on data from LIBRETTO-001: © SciePro -www.stock.adobe.com Selpercatinib (Retevmo) given as an initial treatment for patients with RET fusion-positive advanced or metastatic non–small cell lung cancer (NSCLC) demonstrated a statistically significant and clinically meaningful…

Continue Reading Phase 3 Study of Selpercatinib Meets Primary PFS End Point in NSCLC

Eli Lilly announces positive results for Retevmo in phase 3 lung cancer study

Eli Lilly has announced positive top-line results from a late-stage study of its targeted therapy Retevmo (selpercatinib) versus the current first-line standard of care in certain non-small cell lung cancer (NSCLC) patients. The phase 3 LIBRETTO-431 trial has been evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed with or without Merck’s…

Continue Reading Eli Lilly announces positive results for Retevmo in phase 3 lung cancer study

ctDNA and Lung Cancer | SpringerLink

Abbosh C, Birkbak NJ, Wilson GA, et al (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545:446–451. doi.org/10.1038/nature22364 CrossRef  CAS  PubMed  PubMed Central  Google Scholar  Adalsteinsson VA, Ha G, Freeman SS, et al (2017) Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun…

Continue Reading ctDNA and Lung Cancer | SpringerLink

BioAtla Reports Second Quarter 2023 Financial Results and

Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug Administration (FDA) meeting request for potentially registrational study of BA3011 in non-small cell lung cancer (NSCLC) study; FDA feedback and initiation of study…

Continue Reading BioAtla Reports Second Quarter 2023 Financial Results and

Subtle Differences in NSCLC Could Help Guide Treatment Strategies

Although immunotherapy has become central to first-line treatment for non–small cell lung cancer (NSCLC), a recent study, highlighting squamous cell and non–squamous cell histology, suggests subtle differences in patient populations may be important in caring for patients in some NSCLC subgroups. Study findings were published in Cancer Management and Research….

Continue Reading Subtle Differences in NSCLC Could Help Guide Treatment Strategies

Cytological examination of peripheral blood cell block to diagnose small cell variant ALK-positive anaplastic large cell lymphoma

Case Reports doi: 10.1111/cyt.13281. Online ahead of print. Affiliations Expand Affiliation 1 Department of Diagnostic Pathology, Kanazawa University Hospital, Kanazawa, Japan. Item in Clipboard Case Reports Chie Shimaguchi et al. Cytopathology. 2023. Show details Display options Display options Format AbstractPubMedPMID doi: 10.1111/cyt.13281. Online ahead of print. Affiliation 1 Department of Diagnostic…

Continue Reading Cytological examination of peripheral blood cell block to diagnose small cell variant ALK-positive anaplastic large cell lymphoma

Peptide vaccine turns up the heat in ALK-positive cancers

RESEARCH HIGHLIGHT 31 July 2023 Non-small-cell lung cancer (NSCLC) with rearrangements in anaplastic lymphoma kinase (ALK) is treated with ALK-targeting tyrosine kinase inhibitors. However, resistance and disease progression occur and immune checkpoint inhibitors (ICIs) are not effective. In a recent study, Mota et al. have identified mouse and human immunogenic…

Continue Reading Peptide vaccine turns up the heat in ALK-positive cancers

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer | Antibodies

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer Details Category: Antibodies Published on Friday, 28 July 2023 17:17 Hits: 194 KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus…

Continue Reading Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer | Antibodies

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

July 28, 2023 6:45 am ET KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy KEYNOTE-756 is the first positive Phase 3 study with an immunotherapy regimen to demonstrate a statistically significant improvement in pCR rate in the neoadjuvant setting for this patient…

Continue Reading Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

Perioperative Immunotherapy Improves EFS, But Clouds Optimal Sequencing in Early NSCLC

Heather Wakelee, MD, FASCO Positive event-free survival (EFS) data from the phase 3 AEGEAN (NCT03800134), NEOTORCH (NCT04158440), and KEYNOTE-671 (NCT03425643) trials add further evidence to the benefit of perioperative immunotherapy in early-stage non–small cell lung cancer (NSCLC) but have yet to show clear biomarkers of response beyond PD-L1, explained Heather…

Continue Reading Perioperative Immunotherapy Improves EFS, But Clouds Optimal Sequencing in Early NSCLC

Analysis Supports Consolidative Stem Cell Transplant for CD30+ PTCL Post A+CHP

Image Credit: © Dr_Microbe stock.adobe.com Data from an exploratory subgroups analysis support the use of consolidative stem cell transplant (SCT) in patients with CD30-positive peripheral T-cell lymphomas (PTCL) who achieve complete response (CR) after receiving treatment with brentuximab vedotin (Adcetris) plus cyclophosphamide, doxorubicin, and prednisone (A+CHP).1 Previously, findings from the…

Continue Reading Analysis Supports Consolidative Stem Cell Transplant for CD30+ PTCL Post A+CHP

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer | Antibodies

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer Details Category: Antibodies Published on Wednesday, 19 July 2023 18:10 Hits: 115 KEYTRUDA® (pembrolizumab) plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus…

Continue Reading Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer | Antibodies

Cancers | Free Full-Text | A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer

1. Introduction Typically, tumors in patients with ovarian cancer (OC) are often diagnosed at an advanced stage [1]. Currently, cytoreductive therapy with platinum-based chemotherapy is the mainstay of disease management, to which the majority of patients with OC initially respond. Unfortunately, 70% of these patients eventually develop refractory recurrences [2]….

Continue Reading Cancers | Free Full-Text | A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer

Anaplastic large cell lymphoma in people with breast implants

Christie Brennan, plastic surgery registrar1, Alexandra Moorhouse, primary care physician2, Roxane Vermeland, BIA-ALCL patient advocate3, Peter Kneeshaw, oncoplastic breast surgery consultant4 1Queen Elizabeth Hospital, Birmingham, UK 2Paralowie Family Health, Adelaide, Australia 3Buckeye, Arizona, US (patient author) 4Hull University Teaching Hospitals, Hull, UK Correspondence to C Brennan Christie.brennan{at}nhs.net What you need…

Continue Reading Anaplastic large cell lymphoma in people with breast implants

TROPION-Lung01 Trial of Datopotamab Deruxtecan Meets PFS End Point in NSCLC

Image Credit: © David A. Litman -www.stock.adobe.com Datopotamab deruxtecan (Dato-DXd) led to a statistically significant improvement of progression-free survival (PFS) vs docetaxel for the treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) who received at least 1 prior therapy, according to findings from the TROPION-Lung01…

Continue Reading TROPION-Lung01 Trial of Datopotamab Deruxtecan Meets PFS End Point in NSCLC

AstraZeneca lung cancer drug meets primary endpoint

Positive high-level results from AstraZeneca’s TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with…

Continue Reading AstraZeneca lung cancer drug meets primary endpoint

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

First phase 3 results for Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC demonstrated statistically significant improvement in progression-free survival versus standard chemotherapy in previously treated locally advanced or metastatic disease Trial will continue to assess the dual primary endpoint of overall survival TOKYO & BASKING RIDGE, N.J., July 03, 2023–(BUSINESS…

Continue Reading Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK- ALCL vs. CD30high PTCL, NOS

Aims: The differential diagnosis between ALK-negative anaplastic large cell lymphoma (ALK– ALCL) and peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) with high expression of CD30 (CD30high) are essential. However, no reliable biomarker is available in daily practice except CD30. STAT3 is characteristically activated in ALCL. We aimed to investigate…

Continue Reading Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK- ALCL vs. CD30high PTCL, NOS

Dr Spira on the Ongoing PACIFIC-8 Trial in Unresectable Stage III NSCLC

Alexander I. Spira, MD, PhD, FACP, co-director, Virginia Cancer Specialists Research Institute, director, Thoracic and Phase I Program, clinical assistant professor, Johns Hopkins School of Medicine, discusses the ongoing phase 3 PACIFIC-8 trial (NCT05211895) of durvalumab (Imfinzi) in combination with domvanalimab (AB154) following concurrent chemoradiotherapy in patients with unresectable stage…

Continue Reading Dr Spira on the Ongoing PACIFIC-8 Trial in Unresectable Stage III NSCLC

Fashion Berry Multi Seq Prizm Dn Vp065 Designer Sarees Catal

Delivery Time Gujarat: Next Day by Local Courier (Fedex: 2 days) Mp, Rajasthan, Maharastra : 2-3 Days Other States : 4-8 Days International : 2-8 Days COD Available All INDIA.  Terms of Order Items Ordered: 100% Original Products Sold by us. Products as Shown in Images will be…

Continue Reading Fashion Berry Multi Seq Prizm Dn Vp065 Designer Sarees Catal

Junshi Biosciences Announces Initiation of Phase 3 Study of

SHANGHAI, China, June 29, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the U.S. Food and Drug Administration (“FDA”) has recently agreed a randomized, double-blind, placebo-controlled,…

Continue Reading Junshi Biosciences Announces Initiation of Phase 3 Study of

Recent FDA Actions: June 2023

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma The FDA has granted accelerated approval to enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.1 The regulatory decision was supported by data from the…

Continue Reading Recent FDA Actions: June 2023

Analysis and Therapeutic Targeting of the IL-1R Pathway in Anaplastic Large Cell Lymphoma

. 2023 Jun 20;blood.2022019166. doi: 10.1182/blood.2022019166. Online ahead of print. Zhihui Song  1 , Wenjun Wu  1 , Wei Wei  1 , Wenming Xiao  2 , Michelle Lei  1 , Kathy Cai  3 , Da Wei Huang  4 , Subin Jeong  1 , Jing-Ping Zhang  5 , Hongbo Wang  5 , Marshall Edward Kadin  6 , Thomas A Waldmann  7 , Louis…

Continue Reading Analysis and Therapeutic Targeting of the IL-1R Pathway in Anaplastic Large Cell Lymphoma

Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

RAHWAY, N.J., June 20, 2023–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the Phase 3 KEYNOTE-585 trial, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, followed by adjuvant treatment with KEYTRUDA plus chemotherapy, then KEYTRUDA…

Continue Reading Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

The NCI-MATCH trial: lessons for precision oncology

Jabbour, E. & Kantarjian, H. Chronic myelogenous leukemia: 2020 update on diagnosis, therapy and monitoring. Am. J. Hematol. 95, 691–709 (2020). Article  CAS  PubMed  Google Scholar  Waarts, M. R., Stonestrom, A. J., Park, Y. C. & Levine, R. L. Targeting mutations in cancer. J. Clin. Invest. 132, e154943 (2022). Article …

Continue Reading The NCI-MATCH trial: lessons for precision oncology

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma

Anaplastic large cell lymphoma (ALCL) is the most common type of mature T-cell non-Hodgkin lymphoma in children/adolescents. ALCL is characterized by expression of CD30 in the neoplastic lymphoid cells with frequent expression of anaplastic lymphoma kinase (ALK), especially within the pediatric population. Despite multiple efforts to optimize the use of…

Continue Reading Brentuximab vedotin use in pediatric anaplastic large cell lymphoma

Large Phase 3 clinical trial successfully meets primary

Primary and all key secondary confirmatory endpoints were met, with an improvement in the total combined allergic rhinitis score (TCRS) of 22% compared to placebo (primary endpoint). Results were highly statistically significant and consistent across multiple endpoints The Phase 3 efficacy and safety trial of ALK’s house dust mite tablet…

Continue Reading Large Phase 3 clinical trial successfully meets primary

MD Anderson Research Highlights for June 7, 2023

Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent…

Continue Reading MD Anderson Research Highlights for June 7, 2023

Human Gene Mutation Test Kit Market 2023-2030 Set To Huge

The Human Gene Mutation Test Kit Market, where demand is steadily increasing due to improved purchasing power, is expected to be beneficial for the global market. This comprehensive research report is an exhaustive compilation of market developments and growth factors optimizing their future growth trajectories from accurate data on the…

Continue Reading Human Gene Mutation Test Kit Market 2023-2030 Set To Huge

Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab)

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical…

Continue Reading Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab)

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient subgroups with high unmet needs Late-breaking data to be presented during the 2023 American Society of Clinical Oncology Annual Meeting PRINCETON, N.J., June 04, 2023–(BUSINESS WIRE)–Bristol…

Continue Reading Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

With Perioperative Pembrolizumab, Event-Free Survival for Early-Stage Lung Cancer Was 62% at the Interim Analysis of Phase 3 KEYNOTE-671

Heather A. Wakelee, MD, FASCO, the Professor of Medicine and Chief of the Division of Oncology at Stanford University School of Medicine and the Deputy Director of Stanford Cancer Institute in Stanford, California, and lead study investigator of KEYNOTE-671, joins Pharmacy Times to discuss positive data from KEYNOTE-671, which evaluated perioperative…

Continue Reading With Perioperative Pembrolizumab, Event-Free Survival for Early-Stage Lung Cancer Was 62% at the Interim Analysis of Phase 3 KEYNOTE-671

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer | News

PRINCETON, N.J.–(BUSINESS WIRE)–Jun 4, 2023– Bristol Myers Squibb (NYSE: BMY) today announced four-year follow-up results from the Phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy compared to four cycles of chemotherapy alone in previously untreated patients with…

Continue Reading Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer | News

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer | Antibodies

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer Details Category: Antibodies Published on Sunday, 04 June 2023 15:16 Hits: 87 Patients treated with dual immunotherapy-based combination demonstrate…

Continue Reading Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer | Antibodies

Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance PALO ALTO, Calif., May 31, 2023–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data…

Continue Reading Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

GILEAD AND KITE ONCOLOGY TO SHOWCASE ADVANCES ACROSS THE PIPELINE AIMING TO ADDRESS UNMET NEEDS IN CANCER CARE AT ASCO 2023

GILEAD  AND  KITE  ONCOLOGY  TO  SHOWCASE  ADVANCES  ACROSS  THE  PIPELINE  AIMING  TO  ADDRESS  UNMET  NEEDS  IN  CANCER  CARE  AT  ASCO  2023 – Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Haematologic, Genitourinary, Gastrointestinal, Gynaecological and Other Solid Tumours –   –…

Continue Reading GILEAD AND KITE ONCOLOGY TO SHOWCASE ADVANCES ACROSS THE PIPELINE AIMING TO ADDRESS UNMET NEEDS IN CANCER CARE AT ASCO 2023

A 15-Year-Old Boy with Primary Maxillary Bone Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma Relapsed with Rib Metastasis after Spontaneous Remission of a Maxillary Bone Lesion: A Case Report and Literature Review

Case Reports . 2023 May 12;16(1):308-314. doi: 10.1159/000530459. eCollection 2023 Jan-Dec. Affiliations Expand Affiliations 1 Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan. 2 Department of Clinical Research, Saitama Children’s Medical Center, Saitama, Japan. Free PMC article Item in Clipboard Case Reports Kaito Aizawa et al. Case Rep Oncol….

Continue Reading A 15-Year-Old Boy with Primary Maxillary Bone Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma Relapsed with Rib Metastasis after Spontaneous Remission of a Maxillary Bone Lesion: A Case Report and Literature Review

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla, Inc. Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in 2H23 On track for submitting a meeting request to the Food & Drug Administration (FDA) for the potentially registrational BA3011 Phase 2, part…

Continue Reading BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

Clonal evolution during metastatic spread in high-risk neuroblastoma

Maris, J. M. Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202–2211 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  London, W. B. et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials.Cancer…

Continue Reading Clonal evolution during metastatic spread in high-risk neuroblastoma

Anaplastic large cell lymphoma case misdiagnosed with keloid

Introduction Anaplastic large cell lymphoma (ALCL)is a subtype of peripheral T-cell lymphoma, first reported by Stein et al in 1985, and is usually seen in children and young adults, accounting for 10–15% of paediatric NHL and only 2% of adult NHL.1 Primary cutaneous anaplastic large cell lymphoma (pC-ALCL) is a…

Continue Reading Anaplastic large cell lymphoma case misdiagnosed with keloid

BioAtla Reports First Quarter 2023 Financial Results and

Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in 2H23 On track for submitting a meeting request to the Food & Drug Administration (FDA) for the potentially registrational BA3011 Phase 2, part 2 non-small…

Continue Reading BioAtla Reports First Quarter 2023 Financial Results and

Crizotinib With Chemotherapy Prevents Relapse in Pediatric Patients With ALK1 ALCL, Has Thromboembolic Risk

The addition of crizotinib (CZ) to a standard chemotherapy backbone for anaplastic large-cell lymphoma (ALCL) in children prevented on-therapy disease relapse but was associated with an unexpected increase in the number of thromboembolic events, according to research published in Journal of Clinical Oncology. The findings are from arm CZ of…

Continue Reading Crizotinib With Chemotherapy Prevents Relapse in Pediatric Patients With ALK1 ALCL, Has Thromboembolic Risk

Whole-exome sequencing in Chinese Tibetan patients with VSD

Introduction Congenital heart disease (CHD) refers to cardiovascular malformations caused by abnormal development of cardiac vessels during the fetal period, which is the most common congenital dysplasia and also the main cause of non-infectious death in newborns and infants.1 CHD includes atrial septal defect (ASD), ventricular septal defect (VSD), pulmonary…

Continue Reading Whole-exome sequencing in Chinese Tibetan patients with VSD

Perioperative Toripalimab With Chemo Improves EFS in Resectable Stage III NSCLC

Image Credit: © SciePro [stock.adobe.com] The perioperative use of toripalimab with chemotherapy improved event-free survival (EFS) and reduced risk of disease recurrence, progression events, or death by 60% among patients with resectable stage III non–small cell lung cancer (NSCLC) vs chemotherapy alone, according to findings from the phase 3 Neotorch…

Continue Reading Perioperative Toripalimab With Chemo Improves EFS in Resectable Stage III NSCLC

The therapeutic potential of neurofibromin signaling pathways and binding partners

Bergqvist, C. et al. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J. Rare Dis. 15, 1–23 (2020). Article  Google Scholar  Martin, G. A. et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63, 843–849 (1990)….

Continue Reading The therapeutic potential of neurofibromin signaling pathways and binding partners

The 5th edition of the World Health Organization classification of hematolymphoid tumors: lymphoid neoplasms. Part 2

Now set to be published later this year, the upcoming 5th edition of the World Health Organization (WHO) classification of hematolymphoid tumors (WHO-HAEM5) updates the conceptual framework and reflects major developments that have occurred in the field since 2017. This revised edition contains a restructuring of entities into a hierarchical…

Continue Reading The 5th edition of the World Health Organization classification of hematolymphoid tumors: lymphoid neoplasms. Part 2